Disease and Participant-Related Correlates of Genetic Testing Completion for Hereditary Eye Disorders in a Cohort of over 1400 Patients.

Precision medicine is transforming the management of genetic eye disorders (GEDs). These include conditions like retinitis pigmentosa or Stargardt disease. They are caused by specific mutations in the DNA. Modern treatments, such as the FDA-approved Luxturna, are often gene-specific. Therefore, a definitive molecular diagnosis is the essential gatekeeper to therapy. Researchers seek to understand why some patients navigate the path to a genetic answer. Others remain in a diagnostic limbo.

Historically, the field has relied on large multinational registries. These efforts map the genetic landscape of these diseases. They have identified hundreds of causative genes. However, they often lack the granularity to explain individual failures. There is a gap in understanding the drivers of testing. This paper addresses that gap by analyzing a massive, single-center cohort. It reveals that hurdles to precision eye care are tied to patient demographics and systemic inequities.

The breakdown of the diagnostic pipeline

The transition from a clinical diagnosis to a molecular one is fraught with attrition. Even in advanced tertiary care centers, the "diagnostic odyssey" occurs. This is the prolonged period of uncertainty patients endure while searching for a cause. Currently, the field faces a dual problem. First, not every suspected patient completes necessary testing. Second, even those who do may receive inconclusive or negative results.

This failure mode is not uniform. As shown in, the ability to achieve a molecular diagnosis varies by phenotype (the observable physical characteristics of a disease).

For instance, patients with Usher syndrome (USH) or Stargardt disease (STGD) show high rates of successful diagnosis. Conversely, those with pattern dystrophy (PD) or cone dystrophy (CD) struggle significantly. This suggests genomic medicine is effective for "textbook" cases. However, it leaves patients with heterogeneous or late-onset conditions in the dark.

Mapping the predictors of testing and yield

To dissect these failures, the authors studied 1,466 patients at the Wilmer Eye Institute. Their methodology identifies variables correlating with two milestones: testing completion and diagnostic yield. The researchers used multivariable logistic regression. They specifically used LASSO (least absolute shrinkage and selection operator) regression. This is a method that selects the most relevant predictors by penalizing less important variables.

The study's analytical framework includes three layers: 1. Demographic stratification: Analyzing how race, sex, and age influence testing uptake. 2. Clinical phenotype mapping: Determining how vision loss affects success. Vision loss was measured in logMAR (a logarithmic scale for visual acuity). 3. Genetic architecture profiling: Identifying causative genes, such as ABCA4 or USH2A.

Crucially, the authors did not just accept laboratory results. They performed a systematic review of "variants of uncertain significance" (VUS). These are genetic changes where the clinical impact is currently unknown. They checked these against updated ClinVar annotations. This ensured their diagnostic yield metrics were as accurate as possible.

Evidence of systemic and clinical divergence

The results reveal a stark divide in how different populations benefit from genomic medicine. The paper reports that 74% of the total cohort completed genetic testing. However, this rate drops significantly in certain racial subgroups. Black or African American participants had much lower odds of completing testing (OR 0.40) than White participants. "Other" race participants also saw lower odds (OR 0.57), as shown in .

The disparity in diagnostic success is even more concerning. Among those who completed testing, Black participants were significantly less likely to receive a molecular diagnosis (OR 0.37) than White participants. The authors note a vital distinction. These disparities persisted even when controlling for the time from clinical presentation to testing. This means Black and "Other" race participants are not just facing delays. They receive less informative results even when the timing is equivalent.

On the clinical side, success drivers relate to disease severity. The paper finds that younger age and earlier symptom onset increase the likelihood of a diagnosis. Worse visual acuity is also associated with a higher likelihood of a molecular diagnosis, as shown in .

This suggests a "severity bias." More profound clinical symptoms drive both the urge to test and the chance of finding a genetic culprit.

Limits of the current genomic toolkit

This study provides a massive data point, but it has limits. The authors are transparent about several critical constraints. First, this is a retrospective analysis from a single center. The results may be influenced by selection bias. This happens when more severe or motivated patients gravitate toward specialized academic clinics.

Second, diagnostic yield is constrained by current genomic databases. The paper notes that non-European ancestries are often underrepresented. This creates a biological bottleneck. A patient might have a pathogenic mutation. However, if that mutation is not in a diverse dataset, it stays labeled as a VUS. This leads to an "inconclusive" report. Finally, the study did not account for socioeconomic factors. Variables like insurance coverage likely influence whether a patient can access expensive genetic panels.

The verdict on equitable precision medicine

The verdict is clear. The infrastructure for precision eye care is currently optimized for a specific subset of the population. The research proves that we cannot solve the problem of undiagnosed patients with technology alone. If genomic databases remain Eurocentric, the revolution in gene therapy will be inequitable.

The path forward requires two steps. We must diversify genomic datasets to improve yield for non-European ancestries. We must also address the clinical engagement gap. This ensures the promise of personalized medicine reaches all patients, regardless of their demographic profile.

Figures from the paper